• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical pharmacokinetics of hydralazine.

作者信息

Ludden T M, McNay J L, Shepherd A M, Lin M S

出版信息

Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.

DOI:10.2165/00003088-198207030-00001
PMID:7047041
Abstract
摘要

相似文献

1
Clinical pharmacokinetics of hydralazine.肼屈嗪的临床药代动力学。
Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.
2
Pharmacokinetics of oral hydralazine in chronic heart failure.口服肼屈嗪在慢性心力衰竭中的药代动力学。
Eur J Clin Pharmacol. 1983;25(4):467-73. doi: 10.1007/BF00542113.
3
Clinical pharmacokinetics of hydrallazine.
Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001.
4
Pharmacokinetics of hydralazine and the first pass effect.
Bol Asoc Med P R. 1983 Jun;75(6):276-9.
5
Hydralazine-induced lupus.
South Med J. 2006 Jan;99(1):6-7. doi: 10.1097/01.smj.0000197302.13225.08.
6
Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure.肼屈嗪诱发的狼疮：随着心力衰竭患者使用量增加需保持警惕。
South Med J. 2006 Jan;99(1):18-22. doi: 10.1097/01.smj.0000197121.12352.19.
7
Hydralazine and furosemide kinetics.
Clin Pharmacol Ther. 1982 Sep;32(3):303-6. doi: 10.1038/clpt.1982.164.
8
Determinants of systemic availability of oral hydralazine in heart failure.
Clin Pharmacol Ther. 1985 Nov;38(5):538-43. doi: 10.1038/clpt.1985.220.
9
Hydralazine-induced lupus syndrome.
Ala J Med Sci. 1984 Oct;21(4):427-30.
10
Systemic lupus erythematosus following prolonged treatment with hydralazine.
Ann Allergy. 1971 Jan;29(1):35-6.

引用本文的文献

1
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease.患者分层策略以优化生物源性醛类清除的效果：帕金森病的神经保护方法。
Curr Neuropharmacol. 2021;19(10):1618-1639. doi: 10.2174/1570159X19666210203162617.
2
Drug therapy in haemodialysis patients. Special considerations in the elderly.血液透析患者的药物治疗。老年人的特殊注意事项。
Drugs Aging. 1998 Jun;12(6):441-59. doi: 10.2165/00002512-199812060-00003.
3
Individual variation in first-pass metabolism.

本文引用的文献

1
[Influence of some peripheral vasodilators on renal blood flow].[某些外周血管扩张剂对肾血流量的影响]
Helv Med Acta. 1949 Sep;16(3-4):297-303.
2
[A new group of hypotensive substances with a special mechanism of action].
Experientia. 1950 Jan 15;6(1):19-21. doi: 10.1007/BF02154049.
3
Distribution of hydralazine-1-C-14 after injection into normal mice.向正常小鼠注射1 - C - 14肼苯哒嗪后的分布情况。
J Lab Clin Med. 1962 Mar;59:456-61.
首过代谢的个体差异。
Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.
4
Extrahepatic metabolism of drugs in humans.药物在人体中的肝外代谢。
Clin Pharmacokinet. 1994 Feb;26(2):144-60. doi: 10.2165/00003088-199426020-00007.
5
The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.恩屈嗪在原发性高血压患者和血压正常受试者中的药代动力学。
Br J Clin Pharmacol. 1983 Jul;16(1):27-32. doi: 10.1111/j.1365-2125.1983.tb02139.x.
6
Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?在为高血压患者开肼屈嗪处方时，是否应该确定乙酰化代谢表型？
Eur J Clin Pharmacol. 1984;26(1):39-42. doi: 10.1007/BF00546706.
7
Pharmacokinetics of oral hydralazine in chronic heart failure.口服肼屈嗪在慢性心力衰竭中的药代动力学。
Eur J Clin Pharmacol. 1983;25(4):467-73. doi: 10.1007/BF00542113.
8
First-pass elimination. Basic concepts and clinical consequences.首过消除。基本概念及临床后果。
Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001.
9
Human pharmacokinetics of cadralazine: a new vasodilator.
Eur J Drug Metab Pharmacokinet. 1985 Jul-Sep;10(3):217-23. doi: 10.1007/BF03189745.
10
The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.营养对药物全身可利用性的影响。第二部分：药物代谢与肾排泄。
Klin Wochenschr. 1987 Nov 2;65(21):1062-72. doi: 10.1007/BF01726326.
4
The effect of oral protein and glucose feeding of splanchnic blood flow and oxygen utilization in normal and cirrhotic subjects.口服蛋白质和葡萄糖对正常人和肝硬化患者内脏血流及氧利用的影响。
J Clin Invest. 1955 Jul;34(7, Part 1):1017-25. doi: 10.1172/JCI103151.
5
HUMAN ACETYLATION POLYMORPHISM.人类乙酰化多态性
J Lab Clin Med. 1964 Mar;63:394-403.
6
THE METABOLISM OF 1-HYDRAZINOPHTHALAZINE.1-肼基酞嗪的代谢
J Pharmacol Exp Ther. 1964 Jan;143:7-13.
7
A study of the mechanism of the hemodynamic effects of hydralazine in man.肼屈嗪对人体血流动力学影响机制的研究。
Acta Pharmacol Toxicol (Copenh). 1963;20(Suppl 1):1-53.
8
Physiological disposition of hydralazine (1-hydrazinophthalazine) and a method for its determination in biological fluids.
Arch Int Pharmacodyn Ther. 1961 Jun 1;132:1-15.
9
Studies on the control of hypertension by hyphex. IV. Levels of the agents in urine and blood.
Am J Med Sci. 1954 Oct;228(4):405-16.
10
Rheumatic and febrile syndrome during prolonged hydralazine treatment.长期使用肼屈嗪治疗期间出现的风湿热综合征。
J Am Med Assoc. 1954 Jan 2;154(1):23-9. doi: 10.1001/jama.1954.02940350025006.